SCHEMBL490571

SCHEMBL490571

CC(C)(C)OC(=O)N[C@](CCN(Cc1ccccc1)c1ccc(Br)cc1)(C(=O)O)C1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 3/20 0.41
CACNA1B Q00975 2/20 0.41
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CTSS P25774 3/20 0.36
CTSL P07711 2/20 0.36
CTSB P07858 2/20 0.36
CHRM2 P08172 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
ACE P12821 1/20 0.35
CTSK P43235 1/20 0.35
KCNH2 Q12809 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
CCR5 P51681 1/20 0.35
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490467 0.85 AAK1 (0.41) AKT1KMT2AL3MBTL1CTSSCTSL
SCHEMBL490569 0.78 CACNA1B (0.55) AKT1CACNA1BKMT2ACTSSCTSL
SCHEMBL490586 0.77 CACNA1B (0.41) CACNA1BKMT2ACTSSCTSK
SCHEMBL5320288 0.77 KMT2A (0.46) AKT1CACNA1BKMT2AL3MBTL1CTSS
SCHEMBL3603293 0.75 PPARA (0.48) AKT1CACNA1BCTSSCTSLCTSB
SCHEMBL490832 0.73 PTPN11 (0.41) CACNA1BKMT2AL3MBTL1CTSSCTSB
SCHEMBL490921 0.73 NPC1 (0.42) CACNA1BKMT2AL3MBTL1CTSSCTSK
SCHEMBL376033 0.73 CTSS (0.40) AKT1CACNA1BKMT2AL3MBTL1CTSS
SCHEMBL375865 0.73 CTSS (0.40) AKT1CACNA1BKMT2AL3MBTL1CTSS
SCHEMBL1147463 0.71 CTSS (0.41) CACNA1BKMT2AL3MBTL1CTSSACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106091-B2 Inhibitors of IKK-beta serine-threonine protein kinase CHROMA THERAPEUTICS LTD. (GB) 2012-01-31 US disclosed
EP-2086956-B1 INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE CHROMA THERAPEUTICS LTD (GB) 2011-09-14 EP disclosed
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase CHROMA THERAPEUTICS LTD. (GB) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069473-A1 Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase IKBKB, IKBKE, CHUK AKT1 235/4885CACNA1B 2344/4885KMT2A 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.